Cell differentiation inducer

Details Cell differentiation inducer Cell differentiation inducer

2008-01-08

2008-01-08

Andres, Janet L. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07317028

ABSTRACT:
The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

REFERENCES:
patent: 5541178 (1996-07-01), Betts et al.
patent: 0490667 (1992-06-01), None
patent: 6-179622 (1994-06-01), None
patent: 6-192073 (1994-07-01), None
patent: 6-256181 (1994-09-01), None
patent: 6-305955 (1994-11-01), None
patent: 6-316520 (1994-11-01), None
patent: 7-206765 (1995-08-01), None
patent: 7-258100 (1995-10-01), None
patent: WO96/21648 (1996-07-01), None
patent: WO97/24328 (1997-10-01), None
Hcaplus 1996:518048.
Hcaplus 1994:426079.
Hcaplus 144:80423.
H. Meng-er et al, “Use of All-Trans Retinoic Acid in the Treatment of acute prymyelocytic Leukemia”,Blood, vol. 72, No. 2, Aug. 1988, pp. 567-572.
S. Castaigne et al, “All-Trans Retinoic Acid as a Differentiation Therapy for Acute Promyelocytic Leukemia. I. Clinical Results”,Blood, vol. 76, No. 9, Nov. 1990, pp. 1704-1709.
R. Warrell, Jr., “Differentiation Therapy of Acute Promyelocytic Leukemia With Tretinoin(All-Trans-Retinoic Acid”,The New England Journal of Medicine, vol. 324, No. 20, May 1991, pp. 1385-1393.
I. Olsson et al, “Introduction of Differentiation of the Human Histiocytic Lymphoma Cell Line U-937 b 1α, 25-Dihydroxycholecalciferol”,Cancer Research, vol. 43, Dec. 1983, pp. 5862-5867.
M. Clark et al, “Validation of the General Purpose Tripos 5.2 Force Field”,Journal of Computational Chemistry, vol. 10, No. 8, 1989, pp. 982-1012.
Chemical Abstracts, vol. 63, No. 13, Dec. 20, 1995, Columbus, OH, US; Abstract No. 18311g, B.S. Portnaya et al; XP002051609 & Zhurnal Nauchnoi I Prikladnoi Fotografii I Kinematografii, vol. 10, No. 4, 1965 Moscow ISSN 0044-4561, pp. 278-287.
Chemical Abstracts, vol. 119, No. 25, Dec. 20, 1993, Columbus, OH, US; Abstract No. 270986n, J. Nowakowski: XP002051610 & PL 157 443 B (Uniwersytet Mikolaja Kopernika).
Y.V. Mitin et al, “Rearrangement of ortho-O-aminoacyl, N-acylaminophenol”, Tetrahedron Letters, No. 12, 1979, Oxford GB, pp. 1081-1084, XP002051608.
Marston et al., “On the active principles of the Euphorbiacease. VI, Isolation and biological activities of seven milliamines from Euphorbia milii”, CA Reference 100:64966k, p. 327, vol. 100, 1984.
Kuenzle et al, CA 70: 106484w, Seven membered heterocyclics, XII, Bibenz-[b,f]-1,4-oxazepin-11(10H)-ones and dibenz [b,e]-1,4-oxazipin- 11(5H)-ones, p. 343, 1969.

Affiliated with

Also associated with

Rating

Cell differentiation inducer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell differentiation inducer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell differentiation inducer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2753511